Skip to Content

Bivigam FDA Alerts

The FDA Alert(s) below may be specifically about Bivigam or relate to a group or class of drugs which include Bivigam (immune globulin intravenous).

MedWatch Safety Alerts are distributed by the FDA and published by Following is a list of possible medication recalls, market withdrawals, alerts and warnings. For the latest FDA MedWatch alerts, go here.

Recent FDA Alert(s) for immune globulin intravenous

Bivigam Immune Globulin Intravenous (Human), 10 Percent Liquid, 100 mL Sterile Vial: Recall - Visible Particles Observed

Apr 5, 2013

Audience: Risk Manager, Infectious Disease, Health Professional


[Posted 04/05/2013]

ISSUE: During a routine annual reserve inspection, visible particles were observed in lot number 120016 (Expiration Date: March 31, 2014) of Bivigam Immune Globulin Intravenous (Human), 10% Liquid. Biotest is voluntarily recalling this lot from the market. Inspections of other lots of product have not shown the presence of visible particles.

BACKGROUND: Bivigam is indicated for the treatment of patients with primary humoral immunodeficiency (PI).

RECOMMENDATION: Consignees are asked to examine stocks immediately to determine if you have any of Lot 120016 on hand. If so, discontinue distributing the lot and promptly return all vials to Biotest’s Boca Raton, Florida facility.

Healthcare professionals and patients are encouraged to report adverse events or side effects related to the use of these products to the FDA's MedWatch Safety Information and Adverse Event Reporting Program:

[04/05/2013 - Recall Notice - FDA]

More Bivigam Resources